Moderna is trading at $179.74 (-10.17%) after Phase 3 results showed intismeran with Keytruda reduced recurrence-or-death risk by 42%, below the 49% reported in an earlier study.
- The companies said the Phase 3 result was statistically significant, but investor expectations appear to have been higher.
- The catalyst is company-specific; broader market indicators are modestly higher. No pre-market volume or activity level was provided.